Tumor vasculature and circulating blood components

Tumor vasculature and circulating blood components represent a physiological and systemic target area rather than a single molecular entity. The tumor vasculature consists of the abnormal, disorganized, and leaky blood vessels recruited or formed by a tumor to sustain its high metabolic demands and facilitate the removal of waste products (Source: NIH, National Cancer Institute). This neovasculature is primarily driven by the overproduction of pro-angiogenic factors, most notably Vascular Endothelial Growth Factor (VEGF), which leads to vessels that are structurally and functionally distinct from normal vasculature (Source: PubMed, PMID: 15549096). Circulating blood components include various cell types such as leukocytes, platelets, and circulating tumor cells (CTCs), as well as plasma proteins that contribute to the tumor microenvironment and systemic progression of the disease (Source: Nature Reviews Cancer). Therapeutic interventions directed at this "target" typically involve anti-angiogenic agents that block growth factors like VEGF to starve the tumor of nutrients, or vascular disrupting agents (VDAs) that selectively collapse existing tumor vessels by targeting the endothelial cytoskeleton (Source: PubMed, PMID: 12154364). Additionally, targeting circulating components can interfere with the metastatic cascade, such as using agents that prevent platelet-tumor cell aggregation (Source: Nature Reviews Cancer). While these strategies have become cornerstones of cancer therapy, they are associated with significant safety concerns, including systemic hypertension, proteinuria, and an increased risk of hemorrhage or arterial thromboembolism (Source: StatPearls). Monitoring efficacy often involves measuring circulating biomarkers like VEGF levels or utilizing functional imaging techniques to assess changes in vascular permeability and blood flow (Source: NIH).

Other names

Tumor blood vesselsNeovasculatureTumor microvascular networkHematological compartmentTumor microenvironment (vascular component)

Inhibition of pro-angiogenic signaling pathways (e.g., VEGF/VEGFR), physical disruption of established tumor endothelial cells, and modulation of circulating factors to impede tumor growth and metastatic spread.